Heska (HSKA) Stock Price, News & Analysis

Company Overview

Heska Corporation manufactures and sells diagnostic and specialty products and solutions for veterinary practitioners in the United States, Canada, Mexico, Germany, Italy, Spain, France, Switzerland, Australia, and Malaysia. The company offers Element DC, Element DCX, Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element RC, Element RCX, and Element RC3X chemistry systems for blood chemistry and electrolyte analysis; Element HT5 and scil Vet abc Plus veterinary hematology analyzers to measure blood cell, platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; and Element COAG and Element AIM veterinary analyzers. It also provides HeskaView Telecytology that provides in-clinic automated microscopic slide scanning and computing equipment; IV infusion pumps; digital radiography hardware and mobile digital radiography products; ultrasound systems; Cloudbank, a Web-based image storage solution; point-of-care products to detect antigens and antibodies associated with infectious and parasitic diseases of animals; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels and therapy shots or drops. In addition, the company provides a line of bovine vaccines; biological and pharmaceutical products to other animal health companies; turnkey services comprising research, licensing, production, labeling, and packaging; and validation support and distribution services. It sells its products to veterinarians through a telephone sales force and third-party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. The company was incorporated in 1988 and is based in Loveland, Colorado.

Key Stats

• Today's Range: $119.99 to $119.99
• 50-Day Range: $115.55 to $119.99
• 52-Week Range: $57.83 to $120.03
• Volume: N/A
• Average Volume: 241,932 shs
• Market Capitalization: $1.31 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HSKA Stock Analysis - Frequently Asked Questions

How were Heska's earnings last quarter?

Heska Co. (NASDAQ:HSKA) announced its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.19) EPS for the quarter, missing the consensus estimate of $0.04 by $0.23. The business's quarterly revenue was up 6.4% compared to the same quarter last year.

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Heska investors own include Netflix (NFLX), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 7/19/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: NASDAQ:HSKA
• CIK: 1038133
• Web: www.heska.com
• Phone: (970) 493-7272
• Fax: 970-619-3003
• Employees: 808
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.93)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 266.64
• P/E Growth: N/A
• Net Income: -$19.89 million
• Net Margins: -7.86%
• Pretax Margin: -7.91%
• Return on Equity: 0.94%
• Return on Assets: 0.67%

Debt

• Debt-to-Equity Ratio: 0.23
• Current Ratio: 5.64
• Quick Ratio: 4.12

Sales & Book Value

• Annual Sales: $257.31 million
• Price / Sales: 5.09
• Cash Flow: $1.69 per share
• Price / Cash Flow: 70.99
• Book Value: $39.00 per share
• Price / Book: 3.08

Miscellaneous

• Outstanding Shares: 10,910,000
• Free Float: 9,572,000
• Market Cap: $1.31 billion
• Optionable: Not Optionable
• Beta: 1.58